HBIO Valuation

Harvard Bioscience Inc

Add to Watchlist

Advanced Chart

0.635

+0.073(12.996%)1D

HBIO Relative Valuation

HBIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HBIO is overvalued; if below, it's undervalued.

Historical Valuation

Harvard Bioscience Inc (HBIO) is now in the Fair zone, suggesting that its current forward PE ratio of 6.61 is considered Fairly compared with the five-year average of 23.66. The fair price of Harvard Bioscience Inc (HBIO) is between 0.43 to 3.46 according to relative valuation methord.

Relative Value

Fair Zone

0.43-3.46

Current Price：0.66

Fair

7.47

Trailing

Forward

4.73

EV/EBITDA

Harvard Bioscience Inc. (HBIO) has a current EV/EBITDA of 4.73. The 5-year average EV/EBITDA is 14.29. The thresholds are as follows: Strongly Undervalued below 2.44, Undervalued between 2.44 and 8.36, Fairly Valued between 20.21 and 8.36, Overvalued between 20.21 and 26.14, and Strongly Overvalued above 26.14. The current Forward EV/EBITDA of 4.73 falls within the Undervalued range.

9.53

EV/EBIT

Harvard Bioscience Inc. (HBIO) has a current EV/EBIT of 9.53. The 5-year average EV/EBIT is 18.00. The thresholds are as follows: Strongly Undervalued below -5.18, Undervalued between -5.18 and 6.41, Fairly Valued between 29.60 and 6.41, Overvalued between 29.60 and 41.19, and Strongly Overvalued above 41.19. The current Forward EV/EBIT of 9.53 falls within the Historic Trend Line -Fairly Valued range.

0.28

Harvard Bioscience Inc. (HBIO) has a current PS of 0.28. The 5-year average PS is 1.42. The thresholds are as follows: Strongly Undervalued below -0.01, Undervalued between -0.01 and 0.70, Fairly Valued between 2.13 and 0.70, Overvalued between 2.13 and 2.85, and Strongly Overvalued above 2.85. The current Forward PS of 0.28 falls within the Undervalued range.

8.49

P/OCF

Harvard Bioscience Inc. (HBIO) has a current P/OCF of 8.49. The 5-year average P/OCF is 23.53. The thresholds are as follows: Strongly Undervalued below -56.20, Undervalued between -56.20 and -16.34, Fairly Valued between 63.39 and -16.34, Overvalued between 63.39 and 103.25, and Strongly Overvalued above 103.25. The current Forward P/OCF of 8.49 falls within the Historic Trend Line -Fairly Valued range.

41.73

P/FCF

Harvard Bioscience Inc. (HBIO) has a current P/FCF of 41.73. The 5-year average P/FCF is 18.87. The thresholds are as follows: Strongly Undervalued below -74.97, Undervalued between -74.97 and -28.05, Fairly Valued between 65.80 and -28.05, Overvalued between 65.80 and 112.72, and Strongly Overvalued above 112.72. The current Forward P/FCF of 41.73 falls within the Historic Trend Line -Fairly Valued range.

Harvard Bioscience Inc (HBIO) has a current Price-to-Book (P/B) ratio of 1.78. Compared to its 3-year average P/B ratio of 1.93 , the current P/B ratio is approximately -7.72% higher. Relative to its 5-year average P/B ratio of 2.30, the current P/B ratio is about -22.72% higher. Harvard Bioscience Inc (HBIO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.21%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.91% , the current FCF yield is about -100.00% lower.

2.01

P/B

Median3y

1.93

Median5y

2.30

29.71

FCF Yield

Median3y

6.21

Median5y

3.91

Competitors Valuation Multiple

The average P/S ratio for HBIO's competitors is 0.01, providing a benchmark for relative valuation. Harvard Bioscience Inc Corp (HBIO) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of -6.27%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

HBIO.O

Harvard Bioscience Inc

X T L Biopharmaceuticals Ltd

0.03

679.11M

POAI.O

Predictive Oncology Inc

Milestone Scientific Inc

Precision Optics Corporation Inc

Loss

59.18%

35.49M

Performance Decomposition

Market capitalization of HBIO decreased by 71.14% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.48 to -0.52.

The secondary factor is the Revenue Growth, contributed -6.27%to the performance.

Overall, the performance of HBIO in the past 1 year is driven by P/E Change. Which is more unsustainable.

-6.27%

21.97M → 20.59M

Revenue Growth

-72.64%

-21.86 → -5.98

Margin Expansion

7.77%

-0.48 → -0.52

P/E Change

-71.14%